Ocrelizumab for primary progressive multiple sclerosis

被引：0

作者：

Montalban X

Hauser SL

Kappos L

机构：

来源：

中华物理医学与康复杂志 | 2017年 / 03期

关键词：

D O I：

暂无

中图分类号：

R744.51 [];

学科分类号：

1002 ;

摘要：

BACKGROUND AND OBJECTIVE As B cells are thought to influence the pathogenesis of multiple sclerosis(MS),through antigen presentation,auto antibody production or cytokine secretion,a number of treatment options have focused on manipulating the function of B cells.This study explored the efficacy and safety of Ocrelizumab,a humanized monoclonal antibody that selectively depletes CD20-expressing B cells.

引用

页码：174 / 174

页数：1